Trial Profile
A Phase 1, randomized, fixed sequence study to evaluate the effect of multiple dose administration of modified release diltiazem on the multiple dose pharmacokinetics of CP-945,598 in healthy overweight and obese subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Otenabant (Primary) ; Diltiazem
- Indications Coronary artery disease; Hypertension; Obesity
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 18 Sep 2009 Actual initiation date changed from Apr 2007 to Mar 2007 as reported by ClinicalTrials.gov.
- 15 Apr 2008 New trial record.